Skip to content

Medical assessment of adverse health outcomes in Dutch childhood cancer survivors; a nationwide project; SKION LATER Q2008 onderzoek - Reproductive potential in male survivors of childhood cancer

Medical assessment of adverse health outcomes in Dutch childhood cancer survivors; a nationwide project; SKION LATER Q2008 onderzoek - Reproductive potential in male survivors of childhood cancer - SKION LATER Q2008 - male fertility

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON47702
Enrollment
2700
Registered
2015-05-08
Start date
2016-05-04
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

late effects long-term effects

Interventions

None listed

Sponsors

Stichting Kinderoncologie Nederland
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: adult (> 18 yrs of age) male patients who were treated for childhood cancer (before age 18) in one of the Pediatric Oncology Centers between 1960 and 2001 and who survived for at least 5 years after diagnosis will be included in the SKION LATER study. Participating centres are located in Amsterdam (VU University Medical Center (VUMC)), Groningen (Children's Cancer Center/ University Medical Center Groningen (UMCG)), Rotterdam (Rotterdam Erasmus MC-Sophia (REMC-S), Nijmegen (University Medical Center Nijmegen (UMCN)), Leiden (Leiden University Medical Center (LUMC) and Utrecht (Princess Máxima Center for Pediatric Oncology (PMC)).

Exclusion criteria

Exclusion criteria: diagnosis of childhood cancer with survival less than 5 years, age at diagnosis >17 years or diagnosis while residing in foreign country; females

Design outcomes

Primary

MeasureTime frame
prevalence of subfertility diagnostic value of inhibin B and AMH reproductive history and health of offspring

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)